Close Menu

Lung Cancer

News and reporting on lung cancer.

Using gene expression data combined with bioinformatic analyses, scientists at the University of Georgia and China's Jilin University are developing a urine-based protein biomarker test for gastric cancer that they hope to offer as a direct-to-consumer diagnostic.

The technology, which is being commercialized by start-up firm MagArray, is aimed primarily at drug screening applications, allowing pharmaceutical firms to test compounds against a wide number of proteins for off-target binding, said one of the researchers.

The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.

The company released results from studies of its six-protein diagnostic panel for lung cancer at this month's AACR meeting and this summer may take part in a 300-patient trial sponsored by the NCI's Early Detection Research Network.

The patents cover the selection of non-small cell lung cancer patients, colorectal cancer patients, and head and neck cancer patients for treatment with drugs targeting the epidermal growth-factor receptor pathway.

Med BioGene's shareholders have approved the deal, which gives Precision rights to commercialize Med BioGene's gene expression-based test for early stage non-small-cell lung cancer.

The investigators linked over-expression of the miRNA with increased cancer cell migration from lung cancers.

The new offer comes a month after Signal filed suit against Med BioGene for negotiating a licensing deal for the LungExpress Dx test with Precision Therapeutics.

Called plasmadiscover41, the panel comprises 41 plasma proteins thought to be potential biomarkers for various cancers. The company is also working on a 50- to 60-protein panel for CSF biomarkers that it plans to introduce in the second quarter.

The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.

Pages

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.